E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014740 |
E.1.2 | Term | Endometrial cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014736 |
E.1.2 | Term | Endometrial cancer recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014734 |
E.1.2 | Term | Endometrial cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014741 |
E.1.2 | Term | Endometrial cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the objective response rate (ORR: complete response + partial response [CR + PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. |
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives:
To assess PFS and OS of subjects in this study population when treated with E7080.
To assess disease control rate (DCR:CR+PR+SD >=7 weeks); clinical benefit rate (CBR:CR+PR+durable SD >=23 weeks); and durable SD rate.
To assess safety and tolerability of E7080.
To assess pharmacokinetics profile and pharmacodynamics of E7080 in subjects with advanced endometrial cancer.
Exploratory Objectives:
To explore the effect of E7080 as a function of dose/exposure on tumor volumes
(i.e., as a biomarker of effect on biological growth rate).
To assess the anti-angiogenic effect of E7080 on endometrial carcinomas using
DCE-MRI metrics and the direct anti-tumor effect using DWI-MRI metrics at selected sites.
To identify and evaluate genetic, blood, and tumor biomarkers with respect to the
efficacy-related endpoints of this study.
To identify and evaluate DNA-sequence variants in genes influencing E7080 ADME. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Histologically confirmed diagnosis of endometrial carcinoma.
2) Radiographic evidence of disease progression according to RECIST 1.1 after 1 prior systemic, platinum-based chemotherapy regimen for metastatic or primary unresectable endometrial carcinoma for which no surgical or radiotherapy treatment options exist. Patients with desease progression within 1 year following completion of platinum-based chemotherapy administered as either adjuvant or neoadjuvant treatment will be eligible without the requirement for further systemic treatment. Patients who have received platinum-based adjuvant or neoadjuvant treatment and have disease progression more than 1 year following treatment must receive 1 additional cytotoxic systemic treatment before being eligible for enrollment in this study.
3) Measurable disease meeting the following criteria:
-At least 1 lesion of >/=1.0 cm in the longest diameter for a non-lymph node or >/=1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using CT/MRI. If there is only 1 target lesion, and it is a non-lymph node, it should have a longest diameter of >/=1.5 cm.
-Lesions that have had EBRT or loco-regional therapies such as RF ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.
4) ECOG performance status </=2
5) Adequately controlled BP with or without antihypertensive mediciations, defined as BP </=150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Screening Visit.
6) Adequate renal function defined as calculated creatinine clearance >/=30 mL/min per the Cockcroft and Gault formula
7) Adequate bone marrow function:
-ANC >/=1000/mm3
-Platelets >/=100,000/mm3
-Hemoglobin >/=9.0 g/dL
8) Adequate blood coagulation function as evidenced by an INR </=1.5
9) Adequate liver function:
-Bilirubin </=1.5 x ULN except for unconjugated hyperbilirubinaemia of Gilbert's syndrome
-ALT and AST </=3 x ULN (</=5 x ULN if subject has liver metastases)
10) Females age >/=18 years at the time of informed consent
11) Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-hCG test with a minimum sensitivity of 25 IU/L or equivalent units of beta-hCG). A separate baseline assessment if required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
12) All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
13) Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method, a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the subject must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
14) Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol. |
|
E.4 | Principal exclusion criteria |
1) Brain or leptomeningeal metastases including stable metastases
2) More than 1 prior systemic chemotherapy regimen for metastatic or primary unresectable endometrial carcinoma or any teatment targetting VEGF-directed angiogenesis. There is no restriction regarding prior hormonal therapy
3) Prior systemic anti-tumour therapy within 3 weeks
4) Not fully recovered from prior radiotherapy based on investigator judgment
5) Subjects with >1+ proteinuria on urine dipstick will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with 24-hour urine protein >/=1 g will be ineligible
6) Gastrointestinal malabsorption or any other condition that might affect the absorption of E7080
7) Inability to take oral medication
8) Major surgery within 3 weeks prior to the first dose of study drug
9) Significant cardiobascular impairment: history of congestive heart failure greater than NYHA Class II; unstable angina; myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment
10) Prolongation of QTc interval to >480 msec
11) Bleeding disorder or thrombotic disorder requiring anticoagulant therapy, such as warfarin, or similar agents requiring therapeutic INR monitoring (treatment with low molecular weight heparin [LMWH] allowed)
12) Active hemoptysis (bright red blood of at least 1/2 teaspoon) within 3 weeks prior to the first dose of study drug
13) Known intolerance to the study drug (or any of the excipients)
14) Any medical of other condition which, in the opinion of the investigator, would preclude participation in a clinical trial
15) Any malignancy (except for endometrial cancer, basal or aquamos cell carcinoma of the skin, melanoma in situ, or carcinoma in situ of the cervix) in the past 2 years
16) Previous treatement with an investigational drug withing 30 days prior to the first dose of study drug
17) Females who are pregnant or breastfeeding |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Objective tumour response rate (CR + PR) based on RECIST 1.1. |
|
E.5.2 | Secondary end point(s) |
- Progression-free survival based on RECIST 1.1 and measured as the time from the date of first treatment until the date of first documentation of desease progression or date of death, if death occurs prior to desease progression.
- Overall survival measured as the time from the date of first treatment until the date of death.
- CR based on RECIST 1.1.
- PR based on RECIST 1.1.
- Desease control rate (CR + PR + SD) based on RECIST 1.1 and minimum duration of SD lasting >/= 7 weeks.
- Clinical benefit rate (CR + PR + durable SD) based on RECIST 1.1 and SD lasting >/= 23 weeks.
- Durable SD rate based on RECIST 1.1 and defined as SD lasting >/= 23 weeks.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 29 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Bulgaria |
Hungary |
Poland |
Romania |
Russian Federation |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |